Collectively, these findings illustrate how distinct treatments, exemplified here by Decitabine versus MEK+BCL-XL blockage in the Alb-R26Met cancer model, can drastically modify the immune cell profile in the tumor microenvironment (and in the non-tumoral liver tissue). This evidence concerns the gene BCL2L1 and cancer.